Cleared Traditional

K896582 - DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM)

K896582 is an FDA 510(k) clearance for DIABETES CARE(TM) TEST PACKAGE FOR THE ..., manufactured by Primus, Inc.. The device is a Class 2 Chemistry device with product code LCP cleared through the Traditional 510(k) pathway after a 223-day FDA review.

K896582 · Primus, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1990
Decision
223d
Days
Class 2
Risk

K896582 is an FDA 510(k) clearance for the DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM). Classified as Assay, Glycosylated Hemoglobin (product code LCP), Class II - Special Controls.

Submitted by Primus, Inc. (Kansas City, US). The FDA issued a Cleared decision on June 28, 1990 after a review of 223 days - an extended review cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 864.7470 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Primus, Inc. devices

FDA 510(k) Submission Details - K896582

510(k) Number K896582 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 17, 1989
Decision Date June 28, 1990
Days to Decision 223 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
135d slower than avg
Panel avg: 88d · This submission: 223d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LCP Device Classification - Class 2, Special Controls

Product Code LCP Assay, Glycosylated Hemoglobin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7470
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - LCP Assay, Glycosylated Hemoglobin

All 203
Devices cleared under the same product code (LCP) and FDA review panel - the closest regulatory comparables to K896582.
OPTIMATE HEMOGLOBIN A1C
K896830 · Heraeus Kulzer, Inc. · Sep 1990
ACS NORMAL GLYCOHEMOGLOBIN CONTROL (A1C HGB)
K902455 · Analytical Control Systems, Inc. · Jul 1990
ABNORMAL GLYCOHEMOGLOBIN CONTROL
K902457 · Analytical Control Systems, Inc. · Jul 1990
COLUMNMATE (AUTOMATED COLUMN SYSTEM) 1580, 1581
K901414 · Helena Laboratories · Jun 1990
ROTAG FRUCTOSAMINE (GLYCATED PROTEIN) ASSAY
K900718 · Roche Diagnostic Systems, Inc. · Jun 1990
CLP GLYCOSYLATED HEMOGLOBIN CONTROL-ER
K896334 · Creative Laboratory Products, Inc. · Dec 1989